{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:15:26Z","timestamp":1791256526753,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clml.2025.04.015","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T12:11:53Z","timestamp":1745842313000},"page":"808-818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence of Cardiovascular Events and Carotid Artery USG Abnormalities in Chronic Myeloid Leukemia Patients on Nilotinib Therapy: A 20-Year Single-Center Study"],"prefix":"10.1016","volume":"25","author":[{"given":"Youngeun","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-4636","authenticated-orcid":false,"given":"Yunji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Won","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3031-2200","authenticated-orcid":false,"given":"Soon Hee","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kyun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.clml.2025.04.015_bib0001","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.04.015_bib0002","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.clml.2017.07.006","article-title":"Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up","volume":"17","author":"Aghel","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"10.1016\/j.clml.2025.04.015_bib0003","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2025.04.015_bib0004","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.04.015_bib0005","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.04.015_bib0006","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: eNESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2025.04.015_bib0007","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.clml.2025.04.015_bib0008","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.clml.2025.04.015_bib0009","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2025.04.015_bib0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"10.1016\/j.clml.2025.04.015_bib0011","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.V118.21.2753.2753","article-title":"Nilotinib exerts direct effects on vascular endothelial cells and may act as a co-trigger of atherosclerosis in patients with ph+ CML","volume":"118","author":"Hadzijusufovic","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.04.015_bib0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/ATVBAHA.120.314694","article-title":"Arterial thrombotic complications of tyrosine kinase inhibitors","volume":"41","author":"Wu","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.clml.2025.04.015_bib0013","first-page":"1","article-title":"Cardiovascular complications of targeted therapies for chronic myeloid leukemia","volume":"19","author":"Damrongwatanasuk","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"9624","key":"10.1016\/j.clml.2025.04.015_bib0014","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(08)60694-7","volume":"371","author":"Donnan","year":"2008","journal-title":"Stroke. Lancet."},{"key":"10.1016\/j.clml.2025.04.015_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6617506","article-title":"Predictors for high-risk carotid plaque in asymptomatic Korean population","volume":"2020","author":"Jang","year":"2020","journal-title":"Cardiovasc Ther"},{"issue":"7","key":"10.1016\/j.clml.2025.04.015_bib0016","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1161\/01.STR.0000019127.11189.B5","article-title":"Carotid plaque ultrasonic heterogeneity and severity of stenosis","volume":"33","author":"Aburahma","year":"2002","journal-title":"Stroke"},{"issue":"10","key":"10.1016\/j.clml.2025.04.015_bib0017","doi-asserted-by":"crossref","first-page":"L18","DOI":"10.1016\/S0002-9149(02)02957-0","article-title":"Intima-media thickness: a tool for atherosclerosis imaging and event prediction","volume":"90","author":"O'Leary","year":"2002","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.clml.2025.04.015_bib0018","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3174\/ajnr.A2197","article-title":"Associations between carotid artery wall thickness and cardiovascular risk factors using multidetector CT","volume":"31","author":"Saba","year":"2010","journal-title":"Am J Neuroradiol"},{"issue":"11","key":"10.1016\/j.clml.2025.04.015_bib0019","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1161\/01.STR.31.11.2636","article-title":"Effect of contralateral carotid artery stenosis on carotid ultrasound velocity measurements","volume":"31","author":"Henderson","year":"2000","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.clml.2025.04.015_bib0020","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.12.021","article-title":"Optimal peak systolic velocity thresholds for predicting internal carotid artery stenosis greater than or equal to 50%, 60%, 70%, and 80%","volume":"25","author":"Tokunaga","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"2","key":"10.1016\/j.clml.2025.04.015_bib0021","first-page":"66","article-title":"Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia","volume":"46","author":"Sarlon-Bartoli","year":"2021","journal-title":"J Med Vasc"},{"issue":"3","key":"10.1016\/j.clml.2025.04.015_bib0022","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.04.015_bib0023","article-title":"Incidence and case fatality of stroke in Korea, 2011\u20132020","volume":"46","author":"Moon","year":"2024","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.clml.2025.04.015_bib0024","article-title":"Incidence and case fatality of acute myocardial infarction in Korea, 2011\u20132020","volume":"46","author":"Seo","year":"2024","journal-title":"Epidemiol Health"},{"issue":"1","key":"10.1016\/j.clml.2025.04.015_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-019-1428-0","article-title":"Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups","volume":"17","author":"Gelbenegger","year":"2019","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.clml.2025.04.015_bib0026","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11886-021-01499-y","article-title":"Aspirin, statins, and primary prevention: opportunities for shared decision making in the face of uncertainty","volume":"23","author":"Jhaveri","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.clml.2025.04.015_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0895-0","article-title":"Carotid ultrasound investigation as a prognostic tool for patients with diabetes mellitus","volume":"18","author":"Hoke","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clml.2025.04.015_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12947-015-0041-4","article-title":"Causes of changes in carotid intima-media thickness: a literature review","volume":"13","author":"Qu","year":"2015","journal-title":"Cardiovasc Ultrasound"},{"issue":"12","key":"10.1016\/j.clml.2025.04.015_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144182","article-title":"Impact of cardiovascular risk factors on carotid intima-media thickness and degree of severity: a cross-sectional study","volume":"10","author":"Ren","year":"2015","journal-title":"PLoS One"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:37:50Z","timestamp":1776397070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2152265025001466"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of Cardiovascular Events and Carotid Artery USG Abnormalities in Chronic Myeloid Leukemia Patients on Nilotinib Therapy: A 20-Year Single-Center Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}